Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer
Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine company, has appointed Lisa Wolf as Interim Chief Financial Officer, effective October 1, 2024. Wolf, with 30 years of financial leadership experience, replaces Kimberly Bambach, who will continue as an advisor for strategic transactions and special projects. Wolf has been a senior member of Tivic's finance team for over two years and has contributed to streamlining the company's financial operations. CEO Jennifer Ernst expressed confidence in Wolf's ability to lead Tivic into its next growth phase in bioelectronic therapeutics. The transition aims to maintain continuity while leveraging Wolf's extensive experience in public and private companies across multiple industries.
Tivic Health Systems, Inc. (Nasdaq: TIVC), una compagnia di medicina bioelettronica, ha nominato Lisa Wolf come Chief Financial Officer ad interim, con effetto dal 1 ottobre 2024. Wolf, con 30 anni di esperienza nella leadership finanziaria, sostituisce Kimberly Bambach, che continuerà come consulente per transazioni strategiche e progetti speciali. Wolf è stata un membro senior del team finanziario di Tivic per oltre due anni e ha contribuito a semplificare le operazioni finanziarie dell'azienda. La CEO Jennifer Ernst ha espresso fiducia nella capacità di Wolf di guidare Tivic nella sua prossima fase di crescita nella terapia bioelettronica. La transizione mira a mantenere la continuità sfruttando l'ampia esperienza di Wolf in aziende pubbliche e private in diversi settori.
Tivic Health Systems, Inc. (Nasdaq: TIVC), una compañía de medicina bioelectrónica, ha designado a Lisa Wolf como Directora Financiera Interina, con efectividad a partir del 1 de octubre de 2024. Wolf, con 30 años de experiencia en liderazgo financiero, reemplaza a Kimberly Bambach, quien continuará como asesora en transacciones estratégicas y proyectos especiales. Wolf ha sido un miembro senior del equipo financiero de Tivic durante más de dos años y ha contribuido a optimizar las operaciones financieras de la empresa. La CEO Jennifer Ernst expresó confianza en la capacidad de Wolf para llevar a Tivic a su próxima fase de crecimiento en terapias bioelectrónicas. La transición tiene como objetivo mantener la continuidad mientras se aprovecha la extensa experiencia de Wolf en empresas públicas y privadas en múltiples industrias.
Tivic Health Systems, Inc. (Nasdaq: TIVC), 바이오 전자 의학 회사가 리사 울프를 임시 최고 재무 책임자로 임명했습니다, 2024년 10월 1일부터 효력이 발생합니다. 울프는 30년의 재무 리더십 경험을 가지고 있으며, 전략적 거래 및 특별 프로젝트에 대한 자문 역할을 계속할 키멀리 밤바치를 대체합니다. 울프는 2년 넘게 Tivic의 재무 팀의 선임 구성원으로 활동하며 회사의 재무 운영을 간소화하는 데 기여했습니다. CEO 제니퍼 어스트는 울프가 바이오 전자 치료의 다음 성장 단계로 Tivic을 이끌 능력에 대한 신뢰를 표명했습니다. 이번 전환의 목표는 연속성을 유지하면서 공공 및 민간 기업에서 다양한 산업에 걸친 울프의 광범위한 경험을 활용하는 것입니다.
Tivic Health Systems, Inc. (Nasdaq: TIVC), une société de médecine bioélectronique, a nommé Lisa Wolf au poste de Directrice Financière Intérimaire, à compter du 1er octobre 2024. Wolf, avec 30 ans d'expérience en leadership financier, remplace Kimberly Bambach, qui continuera en tant que conseillère pour des transactions stratégiques et des projets spéciaux. Wolf est membre senior de l'équipe financière de Tivic depuis plus de deux ans et a contribué à rationaliser les opérations financières de l'entreprise. La PDG Jennifer Ernst a exprimé sa confiance dans la capacité de Wolf à diriger Tivic vers sa prochaine phase de croissance dans les thérapeutiques bioélectroniques. La transition vise à maintenir la continuité tout en tirant parti de l'expérience étendue de Wolf dans des entreprises publiques et privées dans divers secteurs.
Tivic Health Systems, Inc. (Nasdaq: TIVC), ein Unternehmen für bioelektronische Medizin, hat Lisa Wolf zur Interim CFO ernannt, die ab dem 1. Oktober 2024 wirksam wird. Wolf, die über 30 Jahre Erfahrung in der finanziellen Führung verfügt, tritt an die Stelle von Kimberly Bambach, die weiterhin als Beraterin für strategische Transaktionen und Sonderprojekte tätig sein wird. Wolf war über zwei Jahre lang ein leitendes Mitglied des Finanzteams von Tivic und hat zur Optimierung der finanziellen Abläufe des Unternehmens beigetragen. CEO Jennifer Ernst äußerte Vertrauen in Wolfs Fähigkeit, Tivic in die nächste Wachstumsphase der bioelektronischen Therapeutika zu führen. Der Übergang zielt darauf ab, Kontinuität zu wahren und gleichzeitig Wolfs umfangreiche Erfahrung in öffentlichen und privaten Unternehmen in verschiedenen Branchen zu nutzen.
- Appointment of experienced Lisa Wolf as Interim CFO with 30 years of financial leadership
- Retention of former CFO Kimberly Bambach as advisor for strategic transactions
- Continuity in financial leadership with Wolf's prior 2-year experience at Tivic
- Streamlining of company's financial operations
- None.
Kimberly Bambach, Ms. Wolf’s predecessor, continues with Tivic as advisor focused on strategic transactions and special projects
“Lisa has served as a senior member of Tivic’s finance team for over two years, and I am delighted to have her taking on an even more pivotal role. I look forward to working with her to lead the company into our next phase of growth in bioelectronic therapeutics,” said Jennifer Ernst, CEO of Tivic.
Ms. Wolf brings 30 years of financial leadership experience in public and private companies, spanning multiple industries. She has built a deep understanding of Tivic’s financial landscape during her tenure serving the company and has a history of significant contributions, including streamlining the company’s financial operations. Ms. Wolf also currently serves as Vice President of Murdock Martell and has previously held positions at Resonant, Inc. and Arthur Andersen.
Ms. Bambach, Ms. Wolf’s predecessor, will continue to play an active role with the company as an advisor, focusing on strategic transactions and other special projects. Her continued involvement will ensure a seamless transition and provide Tivic continued access to her unique expertise in transactions and integrations.
Ms. Ernst continued, “I am also deeply grateful for Kimberly Bambach’s contributions over the past 18 months as we restructured the company to better address current and future market opportunities. I am very pleased she will continue with us in this advisory capacity.”
About Tivic Health
Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of changes to the company’s business strategy, consummation of any strategic transactions, and the company’s need for, and ability to secure when needed, additional working capital. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240913113974/en/
Media Contact:
Morgan Luke
Morgan.Luke@tivichealth.com
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Source: Tivic Health Systems, Inc.
FAQ
When does Lisa Wolf start as Interim CFO of Tivic Health (TIVC)?
What is Lisa Wolf's background before joining Tivic Health (TIVC) as Interim CFO?
What role will Kimberly Bambach have at Tivic Health (TIVC) after stepping down as CFO?
What is Tivic Health's (TIVC) main business focus?
